Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCRX NASDAQ:CLDX NASDAQ:MNKD NASDAQ:ZBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCRXBioCryst Pharmaceuticals$9.34-0.4%$9.22$6.00▼$11.22$2.37B0.554.70 million shs1.85 million shsCLDXCelldex Therapeutics$35.28-0.4%$33.64$19.72▼$40.30$2.77B0.91.21 million shs639,219 shsMNKDMannKind$4.13+6.2%$3.82$2.23▼$6.51$1.28B1.094.67 million shs9.44 million shsZBIOZenas BioPharma$30.39-1.9%$22.97$13.50▼$44.60$1.92B-0.961.08 million shs558,940 shs10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCRXBioCryst Pharmaceuticals0.00%+0.54%-5.66%+4.47%+8.48%CLDXCelldex Therapeutics0.00%-0.20%+3.49%+5.98%+47.80%MNKDMannKind0.00%+2.48%+5.09%+52.96%+0.73%ZBIOZenas BioPharma0.00%+2.91%+23.19%+67.07%+94.56%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCRXBioCryst Pharmaceuticals$9.34-0.4%$9.22$6.00▼$11.22$2.37B0.554.70 million shs1.85 million shsCLDXCelldex Therapeutics$35.28-0.4%$33.64$19.72▼$40.30$2.77B0.91.21 million shs639,219 shsMNKDMannKind$4.13+6.2%$3.82$2.23▼$6.51$1.28B1.094.67 million shs9.44 million shsZBIOZenas BioPharma$30.39-1.9%$22.97$13.50▼$44.60$1.92B-0.961.08 million shs558,940 shs10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCRXBioCryst Pharmaceuticals0.00%+0.54%-5.66%+4.47%+8.48%CLDXCelldex Therapeutics0.00%-0.20%+3.49%+5.98%+47.80%MNKDMannKind0.00%+2.48%+5.09%+52.96%+0.73%ZBIOZenas BioPharma0.00%+2.91%+23.19%+67.07%+94.56%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCRXBioCryst Pharmaceuticals 2.67Moderate Buy$20.80122.70% UpsideCLDXCelldex Therapeutics 2.86Moderate Buy$52.7749.57% UpsideMNKDMannKind 2.50Moderate Buy$8.97117.16% UpsideZBIOZenas BioPharma 2.56Moderate Buy$44.2945.72% UpsideCurrent Analyst Ratings BreakdownLatest MNKD, CLDX, BCRX, and ZBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/23/2026MNKDMannKind HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy7/22/2026CLDXCelldex Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$54.00 ➝ $48.007/22/2026CLDXCelldex Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$44.00 ➝ $40.007/22/2026CLDXCelldex Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$67.00 ➝ $61.007/22/2026CLDXCelldex Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$62.00 ➝ $60.007/20/2026CLDXCelldex Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$90.00 ➝ $100.007/17/2026CLDXCelldex Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/13/2026BCRXBioCryst Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$12.007/9/2026ZBIOZenas BioPharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)7/8/2026MNKDMannKind Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)7/7/2026BCRXBioCryst Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$13.00 ➝ $14.00(Data available from 7/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCRXBioCryst Pharmaceuticals$874.84M2.71$1.24 per share7.54($0.57) per share-16.39CLDXCelldex Therapeutics$1.54M1,798.13N/AN/A$7.93 per share4.45MNKDMannKind$348.97M3.66$0.06 per share66.74($0.17) per share-24.29ZBIOZenas BioPharma$10M191.85N/AN/A$4.51 per share6.74Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCRXBioCryst Pharmaceuticals$263.86M-$1.78N/A14.59N/A-51.71%-76.36%60.12%8/5/2026 (Estimated)CLDXCelldex Therapeutics-$258.76M-$4.26N/AN/AN/AN/A-50.72%-46.59%8/6/2026 (Estimated)MNKDMannKind$5.86M-$0.07N/A59.00N/A-6.63%-11.21%-3.92%8/5/2026 (Estimated)ZBIOZenas BioPharma-$377.74M-$8.47N/AN/AN/AN/A-99.99%-58.06%8/11/2026 (Estimated)Latest MNKD, CLDX, BCRX, and ZBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2026Q2 2026ZBIOZenas BioPharma-$0.89N/AN/AN/A$15.00 millionN/A8/6/2026Q2 2026CLDXCelldex Therapeutics-$1.04N/AN/AN/A$0.74 millionN/A8/5/2026Q2 2026BCRXBioCryst Pharmaceuticals$0.14N/AN/AN/A$183.28 millionN/A8/5/2026Q2 2026MNKDMannKind-$0.02N/AN/AN/A$108.80 millionN/A5/13/2026Q1 2026ZBIOZenas BioPharma-$1.4742-$1.46+$0.0142-$1.46$25.00 millionN/A5/7/2026Q1 2026CLDXCelldex Therapeutics-$1.1472-$1.18-$0.0328-$1.18$0.80 million$0.02 million5/6/2026Q1 2026BCRXBioCryst Pharmaceuticals$0.06-$2.98-$3.04-$2.98$151.12 million$156.41 million5/6/2026Q1 2026MNKDMannKind-$0.02-$0.05-$0.03-$0.05$105.38 million$90.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBCRXBioCryst PharmaceuticalsN/AN/AN/AN/AN/ACLDXCelldex TherapeuticsN/AN/AN/AN/AN/AMNKDMannKindN/AN/AN/AN/AN/AZBIOZenas BioPharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCRXBioCryst PharmaceuticalsN/A1.911.88CLDXCelldex TherapeuticsN/A8.928.92MNKDMannKindN/A1.871.50ZBIOZenas BioPharma1.0411.9411.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCRXBioCryst Pharmaceuticals85.88%CLDXCelldex TherapeuticsN/AMNKDMannKind49.55%ZBIOZenas BioPharmaN/AInsider OwnershipCompanyInsider OwnershipBCRXBioCryst Pharmaceuticals3.80%CLDXCelldex Therapeutics5.20%MNKDMannKind2.60%ZBIOZenas BioPharma22.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCRXBioCryst Pharmaceuticals530254.16 million244.51 millionOptionableCLDXCelldex Therapeutics15078.49 million74.41 millionOptionableMNKDMannKind400308.95 million300.92 millionOptionableZBIOZenas BioPharmaN/A63.13 million49.24 millionN/AMNKD, CLDX, BCRX, and ZBIO HeadlinesRecent News About These Companies125,232 Shares in Zenas BioPharma, Inc. $ZBIO Bought by Walleye Capital LLCJuly 24 at 5:51 AM | marketbeat.comSEB Asset Management AB Invests $3.20 Million in Zenas BioPharma, Inc. $ZBIOJuly 24 at 4:57 AM | marketbeat.comJennison Associates LLC Buys Shares of 250,000 Zenas BioPharma, Inc. $ZBIOJuly 22, 2026 | marketbeat.comZenas BioPharma Grants Inducement Stock Options and RSUs to New EmployeesJuly 17, 2026 | quiverquant.comQZenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 17, 2026 | globenewswire.comZenas BioPharma (NASDAQ:ZBIO) Stock Price Up 7.2% - Time to Buy?July 17, 2026 | marketbeat.comZenas BioPharma: Obexelimab Could Build An Autoimmune FranchiseJuly 14, 2026 | seekingalpha.comZenas BioPharma (ZBIO): Best IPO Stocks with Huge Upside PotentialJuly 11, 2026 | finance.yahoo.comZenas BioPharma (NASDAQ:ZBIO) Trading Down 8% - Here's WhyJuly 10, 2026 | marketbeat.comZenas BioPharma Inc ZBIOJune 27, 2026 | morningstar.comMZenas BioPharma Announces Positive Phase 3 Obexelimab ResultsJune 24, 2026 | theglobeandmail.comZenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction.June 21, 2026 | fool.comZenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 17, 2026 | globenewswire.comZenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert SummitJune 11, 2026 | globenewswire.comZenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR ...June 2, 2026 | finance.yahoo.comZenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of MedicineJune 2, 2026 | globenewswire.comA Look At Zenas BioPharma (ZBIO) Valuation After Strong 1-Year Return And Recent Share Price WeaknessJune 1, 2026 | finance.yahoo.comZenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RDMay 28, 2026 | globenewswire.comZenas Biopharma Inc.May 26, 2026 | money.usnews.comZenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 ...May 19, 2026 | markets.businessinsider.comZenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 CongressMay 19, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMNKD, CLDX, BCRX, and ZBIO Company DescriptionsBioCryst Pharmaceuticals NASDAQ:BCRX$9.34 -0.04 (-0.43%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$9.36 +0.02 (+0.24%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.Celldex Therapeutics NASDAQ:CLDX$35.28 -0.14 (-0.40%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$35.28 -0.01 (-0.01%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.MannKind NASDAQ:MNKD$4.13 +0.24 (+6.17%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$4.09 -0.04 (-0.97%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.Zenas BioPharma NASDAQ:ZBIO$30.39 -0.60 (-1.94%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$30.76 +0.38 (+1.23%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
